• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Topics » General Psychiatry

General Psychiatry
General Psychiatry RSS Feed RSS

Fact Sheet

St. John’s Wort Fact Sheet [G] for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

St. John’s wort may be considered for short-term treatment of mild to moderate depression, especially in patients seeking natural options. However, its extensive drug interaction profile limits broader clinical use.



Read More
Fact Sheet

Saffron Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

A small but growing body of evidence suggests saffron may help with depression, anxiety, and attention-deficit/hyperactivity disorder (ADHD)—particularly in milder cases. 


Read More
Fact Sheet

S-Adenosyl-L-Methionine (SAMe) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

SAMe is a natural compound involved in neurotransmitter synthesis. 



Read More
Fact Sheet

Melatonin Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Melatonin is a hormone secreted by the pineal gland that helps regulate the sleep-wake cycle.


Read More
Fact Sheet

Magnesium Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Most people get enough magnesium from their diet, and while supplementation is sometimes used for anxiety, insomnia, or attention-deficit/hyperactivity disorder (ADHD), the supporting evidence is weak and based on low-quality studies.


Read More
Fact Sheet

Curcumin (Turmeric) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Curcumin, the active ingredient in turmeric, may benefit depression, anxiety, and cognitive health, with some meta-analyses showing small to moderate effect sizes. 


Read More
Fact Sheet

Memantine (Namenda, Namenda XR) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Memantine’s indication (moderate to severe dementia only) may limit its use, but it does boast a unique mechanism of action and has some data to support its usefulness as an augmenter of donepezil.


Read More
Fact Sheet

Zolpidem (Ambien, Edluar, Intermezzo, Zolpimist) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Ambien is the original Z-drug, having been initially FDA approved in 1992.


Read More
Fact Sheet

Zaleplon (Sonata) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Zaleplon is the only sleeping pill that can be taken at 3 or 4 am without causing functional impairment when the patient gets out of bed a few hours later.


Read More
Fact Sheet

Triazolam (Halcion) Fact Sheet [G]

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Puzantian and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Previous 1 2 … 16 17 18 19 20 21 22 23 24 … 219 220 Next
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • shutterstock_2782224449.jpg
    General Psychiatry

    Gender Affirming Care: Fall of the House of Hopkins

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.